Ocugen to Host Webcast on Phase 2 Clinical Trial Data for OCU410 Gene Therapy for Geographic Atrophy

Ocugen will host a webcast on March 24 to discuss Phase 2 clinical trial data for OCU410, a modifier gene therapy for geographic atrophy. Key opinion leaders and Ocugen executive leadership will participate, including Lejla Vajzovic and Jay Chhablani. The webcast will be available on Ocugen's investor site. The company is a biotechnology leader in gene therapies for blindness diseases, with programs in development for inherited retinal diseases and blindness diseases affecting millions.